Aducanumab
| CAS No. | 1384260-65-4 | Cat. No. | BCP24776 |
| Name | Aducanumab | ||
| Synonyms | BIIB037; | ||
| Formula | M. Wt | ||
| Description | Aducanumab is a human monoclonal antibody that is being studied for the treatment of Alzheimer's disease (AD). It is being developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer.The antibody targets aggregated forms of β-amyloid (Aβ) in the hopes of reducing its buildup. | ||
| Pathways | Neuro Signaling Pathway | ||
| Targets | Amyloid β | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.